Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer-Reference-Cited by-同舟云学术

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Published:2018-06 Issue:6 Volume:24 Page:724-730
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Zacharakis Nikolaos,Chinnasamy Harshini,Black Mary,Xu Hui,Lu Yong-Chen^ORCID,Zheng Zhili,Pasetto Anna,Langhan Michelle,Shelton Thomas,Prickett Todd,Gartner Jared,Jia Li,Trebska-McGowan Katarzyna,Somerville Robert P.,Robbins Paul F.,Rosenberg Steven A.,Goff Stephanie L.,Feldman Steven A.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0040-8.pdf

Reference22 articles.

1. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

2. Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet 384, 1109–1117 (2014).

3. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).

4. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

5. Dawood, S. et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J. Clin. Oncol. 26, 4891–4898 (2008).

Cited by 632 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MBFusion: Multi-modal balanced fusion and multi-task learning for cancer diagnosis and prognosis;Computers in Biology and Medicine;2024-10

2. CD4 ⁺ T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy;Science Immunology;2024-09-13

3. Enhancing HLA-DR in Cytotoxic T Lymphocytes is crucial for the development of efficient adoptive T cell Therapies for Breast Cancer;2024-09-06

4. Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines;Molecular Therapy: Oncology;2024-09

5. In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations;Oral Oncology;2024-09